We use cookies to understand how visitors search for and consume the information we provide, so that we can improve their experience. By browsing this website, you indicate your acceptance of the use of such cookies ACCEPTREAD MORE Direct accesses Go to main menu Go to main content Contact Careers YOU ARE VIEWING THE WEBSITE IN ENGLISH EN FR Search the site WHO WE ARE OUR PRODUCTS & PIPELINE OUR TECHNOLOGIES INVESTORS & MEDIA LEADING THE USE OF GENE THERAPY AGAINST BLINDNESS Pause Move to carousel item 1 Move to carousel item 2 Move to carousel item 3 Move to carousel item 4 Move to carousel item 5 Move to carousel item 6 WEBCAST: Compassionate Use Patients in the US • December 2, 2021, at 8 AM EST / 2 PM CET • Live webcast in English: https://bit.ly/31geZ2k READ MORE SECOND CASE OF A PATIENT WHO RECOVERED VISION AFTER TREATMENT WITH GS030 OPTOGENETIC THERAPY The case of a second patient with late-stage retinitis pigmentosa who experienced visual recovery after treatment with GS030 in the PIONEER trial was presented at the Retina Sub-Specialty Day of the 2021 AAO Annual Meeting. Click on the video below to see her perform visual tasks that she had not been able to do before GS030 treatment. READ MORE LUMEVOQ® , GENE THERAPY FOR THE TREATMENT OF LEBER HEREDITARY OPTIC NEUROPATHY (LHON) LUMEVOQ® (GS010) targets Leber Hereditary Optic Neuropathy (LHON) by leveraging a mitochondrial targeting sequence (MTS) proprietary technology platform, arising from research conducted at the Institut de la Vision in Paris, which, when associated with the gene of interest, allows the platform to specifically address defects inside the mitochondria using an AAV vector (Adeno-Associated Virus). GenSight Biologics’ lead product candidate, LUMEVOQ® (GS010; lenadogene nolparvovec), has been submitted for marketing approval in Europe for the treatment of Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease affecting primarily teens and young adults that leads to irreversible blindness. Learn more about LUMEVOQ® OUR PRODUCTS AND PIPELINE GS010 GENE THERAPY + MTS LEBER HEREDITARY OPTIC NEUROPATHY (LHON) GS030 GENE THERAPY + OPTOGENETICS RETINITIS PIGMENTOSA (RP) GS030 GENE THERAPY + OPTOGENETICS GEOGRAPHIC ATROPHY IN DRY-AMD VIEW OUR PRODUCTS & PIPELINE CLINICAL TRIALS LUMEVOQ® (GS010; lenadogene nolparvovec) is completing its clinical development while GS030 is currently running PIONEER Phase I/II CHECK STATUS OUR TECHNOLOGIES GENE THERAPY MITOCHONDRIAL TARGETING SEQUENCE (MTS) OPTOGENETICS VIEW OUR TECHNOLOGIES NEWS & MEDIA PRESS RELEASES EVENTS & PRESENTATIONS 01 December 2021 GenSight Biologics Announces Publication of Non-Human Primate Study Reporting Presence of LUMEVOQ® Vector DNA in Contralateral Eyes After Unilateral Injection 30 November 2021 GenSight Biologics to Host Key Opinion Leader Webcast on Outcomes Among Compassionate Use Patients Treated Bilaterally with LUMEVOQ® in the US 22 November 2021 GenSight Biologics to Host Key Opinion Leader Webcast on Outcomes Among Compassionate Use Patients Treated Bilaterally with LUMEVOQ® in the US ALL PRESS RELEASES PARIS NEW YORK CITY GENSIGHT BIOLOGICS S.A. 74, rue du Faubourg Saint-Antoine 75012 Paris FRANCE CONTACT US  Keyboard shortcuts Map data ©2021 Google Terms of Use Report a map error © 2021 Gensight Biologics TERMS OF USE SITEMAP CONTACT CREDITS